Medpace Holdings, Inc. $MEDP Stock Holdings Boosted by Ameriprise Financial Inc.

Key Points

• Ameriprise Financial Inc. increased its stake in Medpace Holdings, Inc. by 2.7% in Q1, owning 237,390 shares valued at approximately $72.3 million.
• General Counsel Stephen P. Ewald sold 3,000 shares for $1.35 million, reducing his ownership by 22.48%, while insiders sold a total of 114,450 shares worth over $51.7 million in the last three months.
• Medpace reported Q2 earnings surpassing estimates, with $3.10 EPS and a revenue of $603.31 million, marking a 14.2% increase from the previous year.

Ameriprise Financial Inc. boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 237,390 shares of the company's stock after buying an additional 6,226 shares during the quarter. Ameriprise Financial Inc. owned 0.83% of Medpace worth $72,336,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Sone Capital Management LLC acquired a new stake in Medpace during the fourth quarter valued at approximately $1,318,000. GAMMA Investing LLC grew its position in Medpace by 37.1% in the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after buying an additional 83 shares during the last quarter. Fundsmith LLP bought a new position in shares of Medpace in the fourth quarter valued at $42,372,000. Park Avenue Securities LLC lifted its position in shares of Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after acquiring an additional 48 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Medpace by 70.7% during the 1st quarter. UMB Bank n.a. now owns 490 shares of the company's stock worth $149,000 after acquiring an additional 203 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the transaction, the vice president owned 57,500 shares in the company, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 114,450 shares of company stock valued at $51,791,251. Insiders own 20.30% of the company's stock.

Medpace Trading Up 0.5%

Shares of NASDAQ:MEDP opened at $469.29 on Wednesday. The firm has a market cap of $13.18 billion, a price-to-earnings ratio of 34.89, a P/E/G ratio of 2.94 and a beta of 1.42. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30. The business has a fifty day simple moving average of $385.60 and a 200 day simple moving average of $336.58.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the previous year, the company posted $2.75 earnings per share. The business's quarterly revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MEDP. Truist Financial boosted their target price on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Robert W. Baird upped their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, Medpace presently has a consensus rating of "Reduce" and an average price target of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.